of NACC, we examined whether sex-matched PHS predicted dementia onset better than sex-1 0 2 mismatched PHS. The cohort characteristics of NACC can be found in Table 1 .
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The second independent cohort was the Religious Orders Study and Rush Memory and individuals without dementia, all of whom agreed to longitudinal follow-up and organ donation, Rush University. Details of the studies, generation of genomic data, and neuropathologic data 1 1 0 collection have been previously reported 31, 32 . We investigated whether sex-matched PHS has have both genotyping data and autopsy results were included in this analysis (n = 599). Detailed
characteristics of ROSMAP can be found in Table 1 .
For comparison purposes, we also examined the performance of polygenic risk scores 1 1 5
(PRS) in the same manner as described above, except using weights from logistic regressions 1 1 6
while controlling for age-at-ascertainment. This is intended to investigate the benefit of using
Cox regressions in contrast to the standard GWAS approach. Estimating sex dependent hazards for autosomal SNPs
To obtain sex-dependent weights for each SNP, we fitted genome-wide Cox regression models 1 2 1 on men and women separately. This stratified approach was intended to capture sex-specific
effects from autosomal SNPs without explicitly modeling interaction terms. This stratified
approach also allows for differences in the shape of the baseline hazard function between men 1 2 4
and women. As noted in prior studies on sex-dependent genetic effects 9 , although the total sample size for GWAS is thus reduced by half, stratified models are computationally simple and model. More detailed discussion about the hazard estimates from case-control study can be found
in Supplemental Materials. For ADGC data, we used the age-at-onset as the time-to-event and the age-at-last-visit as covariates are the same in the models except age-at-ascertainment is now treated as one of the
covariates. The estimated sex-dependent odds ratios were then used to generate the Deriving polygenic hazard scores and polygenic risk scores
The polygenic scores are the product sum of GWAS obtained weights and genotypes of 1 4 7
individuals in the two test cohorts:
for individual i, the score S i is the product sum of genotypes G ij and weights β j for M SNPs. To 1 4 9 make PHS and PRS comparable, we used the identical pruning and clumping process to select We implemented genome-wide Cox regression for efficiently estimating hazard ratios across 1 6 2 millions of SNPs. P-values of the Cox regressions were obtained using score tests 34 . The logistic
regression GWAS were performed using PLINK. All genome-wide analyses were done using
ADGC data, separately for men and women. In order to provide an intuitive interpretation on the SNPs located within 50Kb regions of the gene body. In NACC, we used 1). Cox regression to examine the predictive power of polygenic 1 6 9 scores on AD age-at-onset, and 2). linear mixed effects model to examine the associations
between polygenic scores and rate of clinical progression, defined as changes in Cognitive
Dementia Rating -Sum of Boxes (CDR-SB). All models were controlled for APOE status
(dosages of e2 and e4) and education levels. The main analysis of NACC included 2628 men and
3448 women. We also examined whether the patterns of association remained constant if we restricted analyses to neuropathologically-confirmed cases; 817 men and 706 women from all results are based on standardized polygenic scores, comparing changes in 1 standard deviation
(SD) of scores. Code availability
The code for the genome-wide Cox regressions will be available on GitHub The summary statistics for genome-wide hazard estimates and gene-based analyses will be found
in the Supplemental Materials. Distribution of hazard weights
Firt, we performed genome-wide Cox regressions for AD age-at-onset on ADGC individuals
(men/women = 7158/10697). The models were controlled for first 5 genetic principal components, APOE status, and recruiting sites (Methods). We noticed that there are different top
hits between men and women ( Figure 2A . and Fure 2B.). Men had a GWAS-significant locus on Additionally, the tau-related gene, MAPT, shows stronger effects on men than on women. and women with wPHS) and sex-mismatched model (men with wPHS and women with mPHS).
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To avoid the confounding of APOE due to imputations, we excluded any genetic variants located
at APOE region (Methods). For clinically determined AD onset, the sex-matched model
consistently performed more accurately than the sex-mismatched model ( Figure 3A ). After 1.32, p < 1e-16) and sex-mismatched PHS has a hazard ratio (HR) of 1.14 (95% CI: 1.09 -1.19, sex-mismatched models is evident for both men and women (Supplemental Figure 1A) . When
we limited our analysis to those with neuropathological disease confirmation (n = 1523), the 2 2 6 crossover effects were consistent (HR: 1.21, p = 2e-9, Figure 3B , Supplemental Figure 1B ) and 2 2 7 retaining significant difference between sex-matched and mismatched models (p = 0.008). and sex-mismatched PHS was statistically significant (p = 0.006). In contrast, PRS from logistic
regressions showed no significant associations regardless of which sex-dependent PRS were Predicting neuropathology in ROSMAP 2 3 7 Figure 4 demonstrates the association strengths across four different types of neuropathology.
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After controlling for age at death, education levels, and APOE status, sex-matched models have
significantly stronger associations than sex-mismatched models for all neuropathological and Braak score, respectively). None of the sex-mismatched models reached statistical 2 4 3 significance in predicting neuropathology based on polygenic components. score, whereas no evident sex differences after controlling for APOE (Figure 4 and Supplemental Understanding the sex-dependent polygenic architecture of AD
By modeling the disease courses as time-to-clinical-onset, the polygenic hazard approach
revealed sex-dependent autosomal effects on AD after controlling for APOE. Sex-matched PHS 2 5 8
showed better prediction of both clinical age-at-onset and neuropathological manifestations than sex-mismatched PHS, implying that genetic risk factors differ between men and women. These Many of the genes highlighted by our analyses have been implicated in AD in prior given the sample size differences. We listed top 10 rank genes in terms of -log10(p) from the regressions of training data were applied to all participants in NACC, yielding both mPHS and controlling APOE and education levels, are shown. A. Prediction of clinically defined AD. B. Prediction in neuropathologically confirmed AD cases, C. Prediction in CDR-SB changes
